DiaSorin
DiaSorin Q3 Revenues Rise 51 Percent on Luminex Acquisition, Recovery of Non-COVID Test Sales
DiaSorin said in Q3 it saw a strong recovery of non-COVID test sales including for latent tuberculosis and other infectious diseases as well as gastrointestinal infections.
DiaSorin Molecular Receives CE Mark for Multiplex COVID-19, Influenza Test
The test detects and differentiates between nucleic acids from SARS-CoV-2 and influenza A/B from the same sample in one reaction well.
DiaSorin Q2 Revenues Rise 20 Percent on SARS-CoV-2 Testing Demand
DiaSorin posted Q2 molecular revenues of €69.4 million, up 23 percent year over year from €56.6 million.
DiaSorin Q1 Revenues Rise 53 Percent on SARS-CoV-2 Testing Demand
The company said that its Q1 revenue growth was driven in part by SARS-CoV-2 test revenues of €102.0 million, booked mainly in the US, Canada, and Europe.
DiaSorin said that the acquisition gives it access to Luminex's multiplexing technology, tests, and instruments and strengthens its MDx product portfolio.
Apr 12, 2021
DiaSorin to Acquire Luminex for $1.8B
Sep 8, 2020
FDA Clears DiaSorin Test for Influenza, RSV
Dec 17, 2019